L'Oréal Adapts Skincare for GLP-1 Weight-Loss Drug Users

L'Oréal is modifying its product development and overall strategy to address the significant impact of GLP-1 weight-loss drugs on the beauty and skincare market, with CEO Nicolas Hieronimus stating on October 23, 2026, that GLP-1 use is "a very important phenomenon" for the beauty industry[2][5]. This strategic shift comes as L'Oréal reported third-quarter sales of €11.56 billion, reflecting 7.7% growth, with skincare sales accelerating[4][5][8][9][10][11][12].

This trend matters to consumers because rapid weight loss from GLP-1 drugs can lead to dermatological concerns like loose skin and facial volume loss, often termed "Ozempic face," creating a new market for beauty products and clinical treatments[2][5][13]. The beauty industry, including major players like L'Oréal, is recognizing this emerging consumer need and adapting its offerings to cater to these specific concerns[1][2][3][4].

What the Records Show

L'Oréal's Chief Innovation and Prospective Officer, Delphine Viguier-Hovasse, confirmed the company is "now testing products on GLP-1 users in separate studies, as this group of consumers is becoming increasingly important and represents a significant number of people worldwide"[1][3][4]. L'Oréal aims to leverage existing brands, such as SkinCeuticals and Kiehl's, and develop new formulations to address side effects like skin sagging[2][5]. The company has also expanded its clinical aesthetics presence by increasing its stake in the dermatology firm Galderma to 20% in December 2025[2][6][7][16][17][18]. Both L'Oréal and Galderma are reportedly conducting trials to develop products for weight-loss drug users concerned about loose skin[2][15][21]. Galderma offers treatments like Sculptra and Restylane, which are marketed by plastic surgeons and aestheticians to these patients, though they are not specifically approved for GLP-1 users[19][20][21].

The broader market indicates a significant opportunity, with Pfizer estimating the obesity drug market could reach $150 billion in annual sales by 2030[13][14][15]. A 2024 report by Medical Insight indicated that 53% of U.S. aesthetics clinics anticipate an influx of new patients due to prescription weight-loss medications, and 43% expect increased demand for treatments addressing associated facial changes[1][13][14][22]. Revenue from clinical treatments for GLP-1 related skin changes is projected to grow from approximately $700 million to $2 billion over the next five years, according to 2025 estimates by Boston Consulting Group[13][14].

The Timeline

In December 2025, L'Oréal increased its stake in Galderma from 10% to 20%, solidifying its presence in the aesthetics market[2][6][7][16][17][18]. On October 23, 2026, L'Oréal CEO Nicolas Hieronimus discussed the impact of GLP-1 drugs during an investor call following the company's third-quarter results[2][5].

What Changed

L'Oréal's product development is now directly targeting the needs of GLP-1 users. The company is actively testing products on this specific consumer group, which represents a shift in focus[1][3]. This adaptation includes developing new formulations and promoting existing products from brands like SkinCeuticals and Kiehl's that can help mitigate effects such as loose skin and facial volume loss[2][5]. The increased investment in Galderma also signals a move towards clinical aesthetic solutions for these new dermatological concerns[2][6].

What L'Oréal Has Said Publicly

During an investor call on October 23, 2026, L'Oréal CEO Nicolas Hieronimus called the rise in GLP-1 use "a very important phenomenon for us" and stated it is "having an impact on beauty consumption and skin care consumption in particular"[2][5]. Delphine Viguier-Hovasse, L'Oréal's Chief Innovation and Prospective Officer, said the company is "now testing products on GLP-1 users in separate studies, as this group of consumers is becoming increasingly important and represents a significant number of people worldwide"[1][3][4]. She also noted that the company is studying this expanding consumer segment due to its growing global importance[4].

What We Could Not Confirm

We could not confirm the specific ingredients or formulations of the new products L'Oréal is developing for GLP-1 users. We also could not confirm the exact timeline for when these new products will be available to consumers. The undisclosed amount L'Oréal paid for the additional stake in Galderma was not specified[16].